title: Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.
abstract: The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD) and vascular dementia (VD). Numerous studies have demonstrated an involvement of the cannabinoid system in neurotransmission, neuropathology and neurobiology of dementias. In addition, several candidate compounds have demonstrated efficacy in vitro. However, some of the substances produced inconclusive results in vivo. Therefore, only few trials have aimed to replicate the effects seen in animal studies in patients. Indeed, the literature on cannabinoid administration in patients is scarce. While preclinical findings suggest causal treatment strategies involving cannabinoids, clinical trials have only assessed the suitability of cannabinoid receptor agonists, antagonists and cannabidiol for the symptomatic treatment of dementia. Further research is needed, including in vivo models of dementia and human studies.
authors.affiliation: University Hospital of Psychiatry, Bolligenstrasse 111, 3000 Bern 60, Switzerland;. walther@puk.unibe.ch.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Walther
authors.affiliation: University Hospital of Psychiatry, Bolligenstrasse 111, 3000 Bern 60, Switzerland;. michael.halpern@gef.be.ch.
authors.forename: Michael
authors.initials: M
authors.lastname: Halpern
keywords: Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; cannabinoids; vascular dementia